ASH 2023 | Estimating transfusion-related medical costs & time burden in patients with MF in SIMPLIFY-1
Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, highlights the findings of an analysis of transfusion-related medical costs and associated time burden in patients with myelofibrosis (MF) treated with momelotinib or ruxolitinib in the Phase III SIMPLIFY-1 trial (NCT01969838). This analysis elucidated that the reductions in transfusion dependence associated with momelotinib treatment led to fewer transfusion visits, resulting in reduced healthcare system costs and time burden. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Board of Directors/Advisory Committee: MorphoSys US
